Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

Avera McKennan Hospital & University Health Center84 enrolled

Overview

This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.

This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants. Retrospective and prospective data will be collected on all subjects before and after pharmacogenetic recommendations have been made. Retrospective data will be collected for the previous 12 months before pharmacogenetic recommendations are made and prospective data will be collected for 12 months after pharmacogenomic recommendations have been made.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Major Depressive Disorder 1

Interventions

Pharmacogenetic testingGENETIC

Psychotropic genotyping panel

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must be taking either an anti-depressant or an anti-psychotic medication * Must provide informed consent * Must have Avera Health Plans insurance coverage * Must have three months of participation in the Avera Care Coordination Program Exclusion Criteria: * Must not be pregnant or breastfeeding * Must not have an active and/or unstable diagnosis of substance abuse * Must not have a primary diagnosis of dementia, bulimia, or anorexia nervosa disorder * Must not have had a previous pharmacogenetic evaluation

Locations (1)

Avera Institute for Human Genetics

Sioux Falls, South Dakota, United States

Outcomes

Primary Outcomes

Depression scores

Compare depression scores at baseline and following pharmacogenetic-guided medication recommendation

Time frame: 12 months

Secondary Outcomes

Economic impact of pharmacogenetic testing

Data from patients' insurance provider will be compared pre- and post-pharmacogenetic testing. Such data may include hospitalizations, clinic visits, ER visits, medication expenses, etc.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.